Chong Kun Dang Pharmaceutical Corp.
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
Efficacy and Safety of TELMINUVO to Stage 2 Hypertension
- Conditions
- Hypertension
- Interventions
- Drug: TELMINUVO Tab. (80/2.5mg)Drug: TELMINUVO Tab. (80/5mg)
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 200
- Registration Number
- NCT01983735
- Locations
- 🇰🇷
The catholic university of Korea Seoul St. Mary's hospital, Seoul, Korea, Republic of
Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin
- Conditions
- Mixed Hyperlipidemia
- Interventions
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2015-02-04
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 476
- Registration Number
- NCT01956201
- Locations
- 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷Pusan National University Hospital, Busan, Korea, Republic of
🇰🇷Kangwon University Hospital, Chuncheon, Korea, Republic of
Bioequivalence Study of Tacrobell Capsule 1mg to Prograf Capsule 1mg
- Conditions
- Immunosuppression
- Interventions
- Drug: Tacrobell capsule 1mg
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 50
- Registration Number
- NCT01910077
- Locations
- 🇰🇷
Seoul national university hospital, Seoul, Korea, Republic of
The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD
- Conditions
- Reflux Esophagitis
- Interventions
- Drug: Newrabell® Tablet 10mg
- First Posted Date
- 2013-05-22
- Last Posted Date
- 2015-09-24
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 39
- Registration Number
- NCT01860482
- Locations
- 🇰🇷
Chonnam National University Hospital, Gwangju, Donggu, Jebongro, Korea, Republic of
🇰🇷Chonnam National University Hwasun Hospital, Gwangju, Hwasun-eup,Hwasun-gun, Korea, Republic of
Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine
- Conditions
- Essential HypertensionHyperlipidemia
- Interventions
- First Posted Date
- 2013-04-29
- Last Posted Date
- 2013-08-01
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT01842230
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.
- Conditions
- Essential HypertensionHyperlipidemia
- Interventions
- First Posted Date
- 2013-04-29
- Last Posted Date
- 2013-08-01
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT01842256
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Evaluate the Efficacy and Safety of My-Rept® Tablet vs. My-Rept® Capsule in Combination With Tacrolimus in Kidney Transplant Patients
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2013-04-29
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 156
- Registration Number
- NCT01842269
- Locations
- 🇰🇷
Maryknoll Medical Center, Busan, Korea, Republic of
🇰🇷Chunbuk National University Hospital, Chonju, Korea, Republic of
🇰🇷Kyungpook National University Hospital, Daegu, Korea, Republic of
Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg
- Conditions
- Congestive Heart FailureEssential HypertensionChronic Stable Angina
- Interventions
- First Posted Date
- 2013-03-28
- Last Posted Date
- 2013-04-01
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 48
- Registration Number
- NCT01819870
- Locations
- 🇰🇷
Kyungpook National University Hospital Clinical Trial Center, Daegu, eok-dong 2(i)-ga Jung-gu, Korea, Republic of
The Study to Evaluate Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients (MYLT1)
- First Posted Date
- 2013-01-11
- Last Posted Date
- 2013-11-07
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 120
- Registration Number
- NCT01766518
- Locations
- 🇰🇷
Asan medical center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Seoul ST Mary's Hospital, Seoul, Korea, Republic of
The Study to Evaluate Efficacy and Safety of Candesartan vs Losartan in Hypertension With Heart Failure (HONOR)
- First Posted Date
- 2013-01-11
- Last Posted Date
- 2014-03-14
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 32
- Registration Number
- NCT01766505
- Locations
- 🇰🇷
Chunbuk National University Hospital, Chonju, Korea, Republic of
🇰🇷Presbyterian Medical Center, Chunju, Korea, Republic of
🇰🇷Chungnam national university hospital, Daejeon, Korea, Republic of